Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.
2.

Preclinical Evaluation of the Short-Term Toxicity of 4-(N)-Docosahexaenoyl 2´, 2´- Difluorodeoxycytidine (DHA-dFdC).

Valdes S, Naguib YW, Finch RA, Baze WB, Jolly CA, Cui Z.

Pharm Res. 2017 Jun;34(6):1224-1232. doi: 10.1007/s11095-017-2139-x. Epub 2017 Mar 28.

3.

Antitumor sulfonylhydrazines: design, structure-activity relationships, resistance mechanisms, and strategies for improving therapeutic utility.

Shyam K, Penketh PG, Baumann RP, Finch RA, Zhu R, Zhu YL, Sartorelli AC.

J Med Chem. 2015 May 14;58(9):3639-71. doi: 10.1021/jm501459c. Epub 2015 Feb 9.

PMID:
25612194
4.

Triplex-forming oligonucleotides targeting c-MYC potentiate the anti-tumor activity of gemcitabine in a mouse model of human cancer.

Boulware SB, Christensen LA, Thames H, Coghlan L, Vasquez KM, Finch RA.

Mol Carcinog. 2014 Sep;53(9):744-52. doi: 10.1002/mc.22026. Epub 2013 May 16.

5.

Ionized calcium levels in umbilical cord blood of women with preeclampsia and normotensive pregnancies.

Yusuf K, Kamaluddeen M, Hasan SU, Al-Awad E, Finch RA, Akierman AR.

J Matern Fetal Neonatal Med. 2012 Feb;25(2):203-5. doi: 10.3109/14767058.2011.561895. Epub 2011 May 17.

PMID:
21574900
6.

Targeting oncogenes to improve breast cancer chemotherapy.

Christensen LA, Finch RA, Booker AJ, Vasquez KM.

Cancer Res. 2006 Apr 15;66(8):4089-94.

7.

High-throughput mouse knockouts provide a functional analysis of the genome.

Friddle CJ, Abuin A, Ramirez-Solis R, Richter LJ, Buxton EC, Edwards J, Finch RA, Gupta A, Hansen G, Holt KH, Hu Y, Huang W, Jaing C, Key BW Jr, Kipp P, Kohlhauff B, Ma ZQ, Markesich D, Newhouse M, Perry T, Platt KA, Potter DG, Qian N, Shaw J, Schrick J, Shi ZZ, Sparks MJ, Tran D, Wann ER, Walke W, Wallace JD, Xu N, Zhu Q, Person C, Sands AT, Zambrowicz BP.

Cold Spring Harb Symp Quant Biol. 2003;68:311-5. No abstract available.

PMID:
15338631
8.

Age-related differences in vincristine toxicity and biodistribution in wild-type and transporter-deficient mice.

Muramatsu T, Johnson DR, Finch RA, Johnson LK, Leffert JJ, Lin ZP, Pizzorno G, Sartorelli AC.

Oncol Res. 2004;14(7-8):331-43.

PMID:
15301424
9.

Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention.

Zambrowicz BP, Abuin A, Ramirez-Solis R, Richter LJ, Piggott J, BeltrandelRio H, Buxton EC, Edwards J, Finch RA, Friddle CJ, Gupta A, Hansen G, Hu Y, Huang W, Jaing C, Key BW Jr, Kipp P, Kohlhauff B, Ma ZQ, Markesich D, Payne R, Potter DG, Qian N, Shaw J, Schrick J, Shi ZZ, Sparks MJ, Van Sligtenhorst I, Vogel P, Walke W, Xu N, Zhu Q, Person C, Sands AT.

Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14109-14. Epub 2003 Nov 10.

10.
11.

mdmx is a negative regulator of p53 activity in vivo.

Finch RA, Donoviel DB, Potter D, Shi M, Fan A, Freed DD, Wang CY, Zambrowicz BP, Ramirez-Solis R, Sands AT, Zhang N.

Cancer Res. 2002 Jun 1;62(11):3221-5.

12.

Human XPA and RPA DNA repair proteins participate in specific recognition of triplex-induced helical distortions.

Vasquez KM, Christensen J, Li L, Finch RA, Glazer PM.

Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5848-53. Epub 2002 Apr 23.

13.

Transport of fluorescein in MDCKII-MRP1 transfected cells and mrp1-knockout mice.

Sun H, Johnson DR, Finch RA, Sartorelli AC, Miller DW, Elmquist WF.

Biochem Biophys Res Commun. 2001 Jun 22;284(4):863-9. Erratum in: Biochem Biophys Res Commun 2001 Aug 10;286(1):227.

PMID:
11409873
14.

Optimization of an exogenous metabolic activation system for FETAX. II. Preliminary evaluation.

Fort DJ, Rogers RL, Paul RR, Stover EL, Finch RA.

Drug Chem Toxicol. 2001 May;24(2):117-27.

PMID:
11360430
15.

Optimization of an exogenous metabolic activation system for FETAX. I. Post-isolation rat liver microsome mixtures.

Fort DJ, Rogers RL, Stover EL, Finch RA.

Drug Chem Toxicol. 2001 May;24(2):103-15.

PMID:
11360429
17.

The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice.

Johnson DR, Finch RA, Lin ZP, Zeiss CJ, Sartorelli AC.

Cancer Res. 2001 Feb 15;61(4):1469-76.

18.

Evaluation of a reproductive toxicity assay using Xenopus laevis: boric acid, cadmium and ethylene glycol monomethyl ether.

Fort DJ, Stover EL, Bantle JA, Dumont JN, Finch RA.

J Appl Toxicol. 2001 Jan-Feb;21(1):41-52.

PMID:
11180279
19.

The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes.

Robbiani DF, Finch RA, Jäger D, Muller WA, Sartorelli AC, Randolph GJ.

Cell. 2000 Nov 22;103(5):757-68.

21.

Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.

Finch RA, Liu M, Grill SP, Rose WC, Loomis R, Vasquez KM, Cheng Y, Sartorelli AC.

Biochem Pharmacol. 2000 Apr 15;59(8):983-91.

PMID:
10692563
22.
23.

Phase III interlaboratory study of FETAX. Part 3. FETAX validation using 12 compounds with and without an exogenous metabolic activation system.

Bantle JA, Finch RA, Fort DJ, Stover EL, Hull M, Kumsher-King M, Gaudet-Hull AM.

J Appl Toxicol. 1999 Nov-Dec;19(6):447-72.

PMID:
10547627
24.

Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity.

Finch RA, Liu MC, Cory AH, Cory JG, Sartorelli AC.

Adv Enzyme Regul. 1999;39:3-12. Review.

PMID:
10470363
25.

New insights into the biology and pharmacology of the multidrug resistance protein (MRP) from gene knockout models.

Rappa G, Finch RA, Sartorelli AC, Lorico A.

Biochem Pharmacol. 1999 Aug 15;58(4):557-62. Review.

PMID:
10413292
26.
27.

Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier.

Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, Piwnica-Worms D.

Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3900-5.

28.

Animals as sentinels of human health hazards of environmental chemicals.

van der Schalie WH, Gardner HS Jr, Bantle JA, De Rosa CT, Finch RA, Reif JS, Reuter RH, Backer LC, Burger J, Folmar LC, Stokes WS.

Environ Health Perspect. 1999 Apr;107(4):309-15.

29.

Identification of a repressor of the differentiation of WEHI-3B D- leukemia cells.

Li J, Finch RA, Xiao W, Sartorelli AC.

Exp Cell Res. 1998 Jul 10;242(1):274-84.

PMID:
9665825
30.

Phase III interlaboratory study of FETAX, Part 2: interlaboratory validation of an exogenous metabolic activation system for frog embryo teratogenesis assay--Xenopus (FETAX).

Fort DJ, Stover EL, Bantle JA, Rayburn JR, Hull MA, Finch RA, Burton DT, Turley SD, Dawson DA, Linder G, Buchwalter D, Dumont JN, Kumsher-King M, Gaudet-Hull AM.

Drug Chem Toxicol. 1998 Feb;21(1):1-14.

PMID:
9530526
31.
32.

Structural and functional relationships of toyocamycin on NPM-translocation.

Finch RA, Revankar GR, Chan PK.

Anticancer Drug Des. 1997 Apr;12(3):205-15.

PMID:
9154111
33.

FETAX interlaboratory validation study: phase III--Part 1 testing.

Bantle JA, Finch RA, Burton DT, Fort DJ, Dawson DA, Linder G, Rayburn JR, Hull M, Kumsher-King M, Gaudet-Hull AM, Turley SD.

J Appl Toxicol. 1996 Nov-Dec;16(6):517-28.

PMID:
8956098
34.

ATP depletion affects NPM translocation and exportation of rRNA from nuclei.

Finch RA, Chan PK.

Biochem Biophys Res Commun. 1996 May 15;222(2):553-8.

PMID:
8670243
35.

GTP gamma S restores nucleophosmin (NPM) localization to nucleoli of GTP-depleted HeLa cells.

Finch RA, Chang DC, Chan PK.

Mol Cell Biochem. 1995 May 24;146(2):171-8.

PMID:
7565647
36.

Initial interlaboratory validation study of FETAX: phase I testing.

Bantle JA, Burton DT, Dawson DA, Dumont JN, Finch RA, Fort DJ, Linder G, Rayburn JR, Buchwalter D, Maurice MA, et al.

J Appl Toxicol. 1994 May-Jun;14(3):213-23.

PMID:
8083483
37.

Nucleolar localization of nucleophosmin/B23 requires GTP.

Finch RA, Revankar GR, Chan PK.

J Biol Chem. 1993 Mar 15;268(8):5823-7.

38.

Teratogenic assessment of four solvents using the Frog Embryo Teratogenesis Assay--Xenopus (FETAX).

Dresser TH, Rivera ER, Hoffmann FJ, Finch RA.

J Appl Toxicol. 1992 Feb;12(1):49-56.

PMID:
1564253
39.
40.
43.
44.

1,2,4-Diazaphosphole nucleosides. Synthesis, structure, and antitumor activity of nucleosides with a lambda 3 phosphorus atom.

Riley TA, Larson SB, Avery TL, Finch RA, Robins RK.

J Med Chem. 1990 Feb;33(2):572-6.

PMID:
1967649
45.

Synthesis and in vivo antitumor activity of 2-amino-9H-purine-6-sulfenamide, -sulfinamide, and -sulfonamide and related purine ribonucleosides.

Revankar GR, Hanna NB, Imamura N, Lewis AF, Larson SB, Finch RA, Avery TL, Robins RK.

J Med Chem. 1990 Jan;33(1):121-8.

PMID:
2296010
46.

Inhibition of growth and modulation of gene expression in human lung carcinoma in athymic mice by site-selective 8-Cl-cyclic adenosine monophosphate.

Ally S, Clair T, Katsaros D, Tortora G, Yokozaki H, Finch RA, Avery TL, Cho-Chung YS.

Cancer Res. 1989 Oct 15;49(20):5650-5.

47.

Inhibition of phosphoribosylpyrophosphate synthetase by 4-methoxy-(MRPP) and 4-amino-8-(D-ribofuranosylamino) pyrimido[5,4-d]pyrimidine (ARPP).

Nord LD, Willis RC, Breen TS, Avery TL, Finch RA, Sanghvi YS, Revankar GR, Robins RK.

Biochem Pharmacol. 1989 Oct 15;38(20):3543-9.

PMID:
2479382
48.

The karyotype of tuleen 346 barley.

Finch RA, Bennett MD.

Theor Appl Genet. 1982 Mar;62(1):53-8. doi: 10.1007/BF00276283.

PMID:
24270535
49.

Hordeum and Secale mitotic genomes lie apart in a hybrid.

Finch RA, Smith JB, Bennett MD.

J Cell Sci. 1981 Dec;52:391-403.

50.

Hypernatremia during lithium and ticarcillin therapy.

Finch RA.

South Med J. 1981 Mar;74(3):376-7.

PMID:
6784244

Supplemental Content

Loading ...
Support Center